CD 20‐positive plasmablastic lymphoma with excellent response to bortezomib combined with rituximab | Zendy

Yan Min | Zendy; Dong Zhaoming | Zendy; Zhao Frank | Zendy; Chauncey Thomas | Zendy; DeaunaLimayo Delva | Zendy; WangRodriguez Jessica | Zendy; Liu Dayu | Zendy; Wang HuanYou | Zendy; Pilz Renate | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

CD 20‐positive plasmablastic lymphoma with excellent response to bortezomib combined with rituximab

Author(s) -

Yan Min,

Dong Zhaoming,

Zhao Frank,

Chauncey Thomas,

DeaunaLimayo Delva,

WangRodriguez Jessica,

Liu Dayu,

Wang HuanYou,

Pilz Renate

Publication year - 2014

Publication title -

european journal of haematology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.904

H-Index - 84

eISSN - 1600-0609

pISSN - 0902-4441

DOI - 10.1111/ejh.12286

Subject(s) - plasmablastic lymphoma , bortezomib , rituximab , lymphoma , medicine , cd38 , regimen , aggressive lymphoma , dexamethasone , oncology , multiple myeloma , immunology , cancer research , biology , stem cell , genetics , cd34

As a distinct type of aggressive mature large B ‐cell lymphoma, plasmablastic lymphoma ( PBL ) poses diagnostic and treatment challenges. PBL is distinguished from other B‐cell lymphomas by the presence of plasmacytic differentiation markers such as CD 38, CD 138, and MUM 1. Clinically, PBL s from oral and extra‐oral sites are rapidly progressive tumors with frequent relapse after treatment with standard diffuse large B ‐cell lymphoma regimens. Here, we report a near‐complete response of one patient with relapsed PBL following treatment with a non‐cytotoxic regimen containing bortezomib, rituximab, and dexamethasone.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research